Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer

Tas, Faruk; Derin, Duygu; Guney, Pınar; Aydiner, Adnan; Topuz, Erkan

doi:10.1007/s10147-007-0757-8

Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer

Atıf İçin Kopyala

Tas F., Derin D., Guney N., Aydiner A., Topuz E.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.13, sa.4, ss.330-334, 2008 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 13 Sayı: 4
Basım Tarihi: 2008
Doi Numarası: 10.1007/s10147-007-0757-8
Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.330-334
İstanbul Üniversitesi Adresli: Evet

Özet

Background. Pegylated liposomal doxorubicin (PLD) is the only nonplatinum agent to significantly improve survival in patients with platinum-sensitive recurrent ovarian cancer. The present study was designed to assess the efficacy and safety of PLD plus cisplatin combination therapy in these patients.